Anthropic: Claude cuts drug design work in six lab partnerships

Anthropic frames its life sciences push around a simple observation: drug development has no single bottleneck. Identifying a target, designing a molecule, optimizing it for manufacturing, drafting regulatory filings and running trials are separate problems, so the company argues the way to find them is to work inside real drug programs across many disease areas and stages. That is what the six partnerships are for, and Anthropic says the work has already led it to prioritize specific improvements to its models.

The case studies span very different tasks. Generate Biomedicines used Claude Code to propose designs for part of a CAR T-cell therapy's genetic instructions, and one design about 70% shorter performed better in lab tests. Divergence Labs had Claude generate roughly 35,000 antibody designs in about a month, and early tests found hits for both arms of its food-allergy approach. BigHat Biosciences tested about 1,010 variants in about 10 weeks, and when the team suspected its standard metrics were misleading, Claude reanalyzed the raw data and proposed alternatives. Enveda aimed Claude at manufacturing documents and regulatory drafts.

Beyond the partnerships, Anthropic has begun running its own programs. It acquired Mithril Medicine, a one-person company whose founder, Cody Tranbarger, used Claude to coordinate contracts, logistics and experiments with 11 external labs; a possible treatment for one form of muscular dystrophy went from idea to promising results in mice in less than 18 months. Anthropic is careful to note the research is still early and mostly preclinical, and it is pairing the effort with access programs such as Claude Science and a Life Sciences Verification Program for trusted organizations.